Search bioRxiv⌕ Search

Biology subjects

Vlasma, J. R.

Publications and source records attributed to Vlasma, J. R..

2 recordsLinked to original sources

A repair-associated bronchial epithelial differentiation trajectory through KRT14+ basal and hillock-like cells drives airway inflammation and remodelling in childhood-onset asthma

The bronchial epithelium in asthma is vulnerable to damage and has impaired barrier function, but the mechanisms by which it contributes to airway inflammation and remodelling remain unclear. Here, we dissect these epithelial and immunological disease mechanisms by establishing a comprehensive single cell atlas of the bronchial wall from 21 patients with childhood-onset asthma and 25 matched healthy controls. We identify a novel asthma-associated non-canonical epithelial differentiation trajectory in which a repair-associated KLF4+ basal cell subset differentiates into KRT13+ hillock-like cells through a proliferative KRT14+ intermediate. In vitro cultured matched primary bronchial epithelial cells show that this trajectory is retained in absence of exogenous factors. We find that IL-13 induces hillock-like cell differentiation into CEACAM5hi goblet cells, driving goblet cell metaplasia. Repair-associated basal cells and transitioning CEACAM5hi hillock-like cells strongly contribute to airway inflammation and remodelling. In turn, dendritic cells and mast cells promote a state of highly active epithelial differentiation, which shows increased multiciliated cell fate decisions, in concordance with an increase in multiciliated cell death observed in asthma. Proportions of the epithelial cells of the non-canonical differentiation trajectory are associated with clinical outcomes such as disease severity, FeNO, and small airway function.

immunology↗

Receptor agonist of NFκB signaling ligand directs lung epithelial cell expansion through RANK signaling

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, with progressive emphysema driven by repeated epithelial damage and impaired repair. Recently, we found that secretion of the osteokine "receptor agonist of nuclear factor {kappa}B signaling ligand" (RANKL) is higher in lung fibroblasts from patients with COPD compared to control and that RANKL represses lung epithelial cell death. However, the underlying mechanism, its cross-species conservation and the involved epithelial cell types remain unclear. To investigate how RANKL affects lung epithelial cells, we used primary lung organoids from human and mouse epithelial cells and showed that RANKL supplementation increased alveolar organoid forming capacity in these cultures compared to vehicle-treated controls. In elastase-treated mice, RANKL was able to rescue the elastase-induced loss of epithelial cells compared to vehicle-treated controls and it augmented the proportion of epithelial cells in transitional states expressing Krt8 and MHCII. Using A549 epithelial cells to investigate whether RANK or the alternative receptor for RANKL, "leucine-rich repeat-containing G-protein coupled receptor 4" (LGR4) were responding to RANKL treatment, we found that RANKL most likely acts through RANK These results suggest that RANKL may enhance stem cell survival of primarily alveolar epithelial cells in both mice and humans. We therefore conclude that RANKL is another osteokine, in addition to periostin, osteopontin, osteoglycin, and osteoprotegerin, that has a role in lung tissue repair and that its signaling pathway could be explored for therapeutic applications. New & NoteworthyRANKL enhances human and murine alveolar epithelial cell expansion. Using organoids and an elastase injury model, we show RANKL promotes alveolar epithelial type II cell expansion and rescues transitional cell type loss. RANKL/RANK signaling therefore emerges as a conserved lung regenerative pathway and may be a potential therapeutic target for diseases like COPD with impaired epithelial repair.

cell biology↗